Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. H. | - |
dc.contributor.author | Park, J. Y. | - |
dc.contributor.author | Oh, M. M. | - |
dc.contributor.author | Lee, J. G. | - |
dc.contributor.author | Kwon, S. -S. | - |
dc.contributor.author | Bae, J. H. | - |
dc.date.accessioned | 2021-09-06T12:17:54Z | - |
dc.date.available | 2021-09-06T12:17:54Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 1368-5031 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106714 | - |
dc.description.abstract | Aims: To evaluate the efficacy and treatment satisfaction with low-dose (0.2 mg) tamsulosin in patients with symptomatic benign prostatic hyperplasia (BPH), and to investigate individual lower urinary tract symptoms according to treatment satisfaction. Methods: A cross-sectional study was conducted in a total sample of 2574 patients from multiple centres. International Prostate Symptom Score (IPSS), prostate volume, uroflowmetry and combined medications were reviewed. Detailed questionnaires were used to assess treatment satisfaction and IPSS 8 weeks after treatment with low-dose tamsulosin. Results: After 8 weeks of treatment with low-dose tamsulosin, IPSS improved significantly. Among the 2574 patients, 1,630 (63.42%) were satisfied and 940 patients (36.50%) were dissatisfied with low-dose tamsulosin. The reasons for dissatisfaction included efficacy problems (84.66%) and side effects (3.72%). Treatment satisfaction was affected by symptom duration, baseline IPSS, and prostate size (p = 0.0441, < 0.001, < 0.009, respectively). IPSS voiding (IPSS-V) and IPSS storage (IPSS-S) after treatment differed significantly depending on the degree of satisfaction (p < 0.001). IPSS-V after treatment did not improve in patients who were not satisfied or totally not satisfied (p = 0.170, 0.240, respectively). All the individual IPSS items except urgency (p = 0.1436) varied significantly with the degree of satisfaction (p < 0.001). Conclusions: Treating symptomatic BPH with low-dose tamsulosin improved IPSS, but more than one-third of patients were dissatisfied with the treatment. The main reason for dissatisfaction was efficacy problems, and the degree of satisfaction was related to symptom duration, baseline IPSS, and prostate size, and also to IPSS-V. In patients with severe LUTS, the tamsulosin dose should be increased earlier. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject | EFFICACY | - |
dc.subject | TOLERABILITY | - |
dc.subject | METAANALYSIS | - |
dc.subject | TERAZOSIN | - |
dc.subject | SAFETY | - |
dc.subject | SCORE | - |
dc.title | Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, J. Y. | - |
dc.contributor.affiliatedAuthor | Oh, M. M. | - |
dc.contributor.affiliatedAuthor | Lee, J. G. | - |
dc.contributor.affiliatedAuthor | Kwon, S. -S. | - |
dc.contributor.affiliatedAuthor | Bae, J. H. | - |
dc.identifier.doi | 10.1111/j.1742-1241.2012.02985.x | - |
dc.identifier.scopusid | 2-s2.0-84869419405 | - |
dc.identifier.wosid | 000311382300012 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, v.66, no.12, pp.1209 - 1215 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | - |
dc.citation.volume | 66 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1209 | - |
dc.citation.endPage | 1215 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | TERAZOSIN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | SCORE | - |
dc.subject.keywordAuthor | SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST | - |
dc.subject.keywordAuthor | QUALITY-OF-LIFE | - |
dc.subject.keywordAuthor | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject.keywordAuthor | CHINESE PATIENTS | - |
dc.subject.keywordAuthor | EFFICACY | - |
dc.subject.keywordAuthor | OBSTRUCTION | - |
dc.subject.keywordAuthor | BPH | - |
dc.subject.keywordAuthor | TOLERABILITY | - |
dc.subject.keywordAuthor | METAANALYSIS | - |
dc.subject.keywordAuthor | TERAZOSIN | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.